Antitachycardia devices: realities and promises

Krannert Institute of Cardiology, Indianapolis, Indiana 46202-4800.

Nonpharmacologic therapy for ventricular arrhythmias has gained growing attention with the development of the implantable cardioverter-defibrillator. In addition, the reports of adverse effects of drug therapy from several studies, including the Cardiac Arrhythmia Suppression Trial (CAST), have supported the need for these devices. The development of new implantable cardioverter-defibrillators that have the capability of antitachycardia pacing, bradycardia pacing, cardioversion and defibrillation has enhanced their clinical utility. The currently available implantable cardioverter-defibrillators have been shown to significantly improve survival after sudden cardiac arrest in patients with life-threatening ventricular arrhythmias. Newer devices with expanded capabilities may reduce mortality even further. In this report the features of currently available antitachycardia devices and implantable cardioverter-defibrillators are reviewed and the features and current implant data on newer antitachycardia devices are discussed.

This article has been cited by other articles:

				G. J. Fahy, E. B. Sgarbossa, P. J. Tchou, and S. L. Pinski Hospital Readmission in Patients Treated With Tiered-Therapy Implantable Defibrillators Circulation, September 15, 1996; 94(6): 1350 - 1356. [Abstract] [Full Text]

				S. L. Pinski and G. J. Fahy The Proarrhythmic Potential of Implantable Cardioverter-Defibrillators Circulation, September 15, 1995; 92(6): 1651 - 1664. [Abstract] [Full Text]